Check for updates

OPEN ACCESS

EDITED BY Sandeep Dhindsa, Saint Louis University, United States

REVIEWED BY Francesco Salis, University of Cagliari, Italy Rick I. Meijer, Radboud University Medical Centre, Netherlands

*CORRESPONDENCE Jian-Feng Qu geoffrey-197830@163.com Yang-Kun Chen cykun78@163.com

RECEIVED 19 October 2023 ACCEPTED 01 December 2023 PUBLISHED 20 December 2023

CITATION

Liang Z-Y, Lu Z-H, Qu J-F and Chen Y-K (2023) Clinical and imaging associations for non-ketotic hyperglycemic chorea: a casecontrol study. *Front. Endocrinol.* 14:1323942. doi: 10.3389/fendo.2023.1323942

COPYRIGHT

© 2023 Liang, Lu, Qu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Clinical and imaging associations for non-ketotic hyperglycemic chorea: a case-control study

Zhuo-Yuan Liang^{1,2}, Zhi-Hao Lu^{1,2}, Jian-Feng Qu^{1,2*} and Yang-Kun Chen^{1,2*}

¹Department of Neurology, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, China, ²Intelligent Brain Imaging and Brain Function Laboratory (Dongguan Key Laboratory), Dongguan People's Hospital, Dongguan, Guangdong, China

Background: The non-ketotic hyperglycemic chorea (NKHC) was a rare complication for patients with diabetes mellitus, but not been well studied. In the present research, we aimed to investigate the clinical and imaging characteristics of NKHC and explore the potential association.

Methods: We performed a case-control study with patients diagnosed as NKHC. The patients with group of NKHC were retrospectively recruited, while the matched group were set to screened patients with diabetes mellitus but no NKHC at a 1:3 ratio. The clinical and imaging data were collected for all the participants of the two groups. Firstly, Correlation analysis was conducted to test the difference of all the variables between the NKHC group and matched group. Then, the putative associated factors for NKHC were further identified.

Results: Eleven men and 9 women with NKHC and 60 matched participants were analyzed. The mean age of the NKHC group was 68.5 \pm 14.9 years. Participants with NKHC were more likely to have a higher glycosylated hemoglobin (HbA1c) level (13 \pm 2.82 vs. 10.57 \pm 2.71, *P*<0.001), and a higher frequency of renal dysfunction (estimated glomerular filtration rates <60 ml/min/1.73m²) (55% vs. 20%, *P*=0.005). Logistic regression analyses showed that both higher HbA1c and renal dysfunction were significantly correlated with NKHC.

Conclusion: A higher value of HbA1c and renal dysfunction may be associated with the occurrence of NKHC.

KEYWORDS

non-ketotic hyperglycemic chorea, diabetes mellitus, case-control study, renal dysfunction, association

01

Introduction

Chorea is a rare complication of diabetes mellitus reported more frequently in older Asian women (1) and was first described by Bedwell (2). Yahikozawa et al. suggested that a combination of choreatic movements and striatal hyperintensity on T1weighted MRI in diabetic patients may constitute a unique syndrome (3). Non-ketotic hyperglycemic chorea (NKHC), which manifests as a bilateral or unilateral chorea with hyperdensive lesions on nonenhanced computed tomography (CT) and hyperintensive lesions on T1-weighted magnetic resonance imaging (MRI) (4). Patients with NKHC show continuous, non-rhythmic, and involuntary movement of their limbs, that commonly persists for 1–2 weeks, or may last several months or years (1, 5). This movement disorder causes severe impairments in their activities of daily living. The prevalence of NKHC is underestimated with the rate of 1/100,000 due to the unfamiliarity and misdiagnosed by physicians (6).

Actually, previous study demonstrated that chorea, hyperglycemia, neuroimaging abnormalities in basal ganglia were "triple signs" for NKHC (7, 8). Sporadic case reports and literature reviews have suggested that genetic background, an age-related susceptibility, a sex predisposition, and glucose metabolism disorders might be involved in the development of NKHC (1, 5, 9). Rapid depleted GABA and acetylcholine in non-ketotic hyperglycemia cause a basal ganglia dysfunction and subsequent chorea (5). Reversible hyperintensive lesions on T1-weighted MRI may be the result of regional hypoperfusion, selective neuronal loss, gliosis and reactive astrocytosis, rather than cerebral infarction (10-12). Biopsy and post-mortem pathological studies have revealed that lesions of basal ganglia contained gliotic brain tissue, abundant gemistocytes, and hyalinosis of blood vessels (7). Necrosis, thickening of arteriole walls, narrowed vessel lumens, extravasation of red blood cells, capillary proliferation, lymphocytic infiltration, and macrophage invasion were also notable (10). However, most of the previous studies were case reports that only described the clinical and imaging manifestations of the disease (4, 13, 14). The associations between the clinical and neuroimaging factors for the NKHC have not been well characterized. In some case reports, patients with NKHC did not show a high level of blood glucose on admission (5). Most notably, the elevated glycosylated hemoglobin (HbA1c) was observed in some cases (5, 8). Therefore, we aimed to investigate the putative clinical and imaging characteristics of NKHC.

Methods

Research design and participants

We retrospectively recruited patients with NKHC who were admitted to the Department of Neurology or the Department of Endocrinology in the Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital) between January 1st, 2012, and July 1st, 2023. The clinical definition of NKHC was according to Chua et al. (8), including: 1) the presence of bilateral or unilateral choreatic movements, 2) a history of diabetes mellitus, or a diagnosis of diabetes mellitus according to the 1999 World Health Organization criteria (15) although with normal blood glucose on admission, 3) absence of ketonemia, 4) hyperdensive lesions on brain CT or hyperintensive lesions on T1-MRI, what are mainly located on the unilateral/bilateral basal ganglia. Meanwhile, patients did not comply with the possible differential diagnoses of chorea combining to diabetes mellitus, along with wiping out the other possible diseases with basal ganglia neuroimaging abnormal findings. The inclusion criteria for the present study were (1) age >18 years; (2) be accordant to the criteria of clinical definition of NKHC; (3) the presence of bilateral or unilateral choreatic movements; and (4) complete data both of clinical and brain imaging (Both CT and MRI) records. The exclusion criteria were (1) acute stroke (including ischemic or hemorrhagic stroke) within the preceding 2 weeks; (2) the presence of a severe comorbidity (e.g., liver, kidney, heart, or respiratory failure; traumatic brain injury; or malignant tumor); (3) the presence of other movement disorders (e.g., Parkinson's disease, Huntington's disease, neuroacanthocytosis, paroxysmal kinesigenic dyskinesia or other choreatic diseases); (4) the presence of other metabolic disorders (e.g., hypocalcemia, and thiamine or nutritional deficiencies) and (5) the use of medication(e.g., dopaminergic medication, dopamine blocking agents, dopamine depleting agents, anti-seizure medications, calcium channel blockers, central nervous system stimulants, tricyclic, antihistamines, antidepressants and isoniazid) that has the potential to induce chorea-like symptoms during the preceding 2 weeks.

A control group of patients with diabetes mellitus but without NKHC were was carefully selected to match the NKHC at a ratio of 1:3. The members of this group were admitted to our hospital during the same period of time (\pm 3 months) and were carefully matched for sex, age (\pm 2 years) and admission blood glucose concentration (\pm 1 mmol/L). To be included in the non-NKHC group, patients had to meet the following criteria: (1) age >18 years; (2) diagnosis of diabetes mellitus made according to the 1999 World Health Organization criteria (14) and no diabetic ketoacidosis; (3) availability of complete medical and brain imaging (CT or MRI) records; and (4) the absence of movement disorders. The exclusion criteria were the same as for the NKHC group.

Clinical data collection

We collected demographic and clinical information, including age, sex, history of diabetes mellitus (the disease duration, drug use, and self-monitoring of blood glucose) and the results of laboratory testing (e.g., blood glucose concentration on admission, HbA1c, liver enzyme activities, serum creatinine, and serum lipid concentrations). The self-monitoring of blood glucose (SMBG) was defined as: glucose monitoring was performed at least once per day in patients treated with insulin or at least three times per week in patients treated with oral agents or diet lonely. Renal function was assessed by estimated glomerular filtration rate (eGFR) was calculated with CKD-EPI equation (16). Renal dysfunction was defined as: eGFR < 60 ml/min/1.73m².

Neuroimaging measurements

All the participants in the two groups had data of brain CT scanning (Brilliance, Philips, Amsterdam, Netherlands) and MRI examination using a 1.5-T (Achieva, Philips) or a 3.0-T (Sonata, Siemens Medical, Erlangen, Germany) system within 48 hours of admission. The basic MRI sequences including: T1-weighted imaging (T1WI), T2-weighted imaging (T2WI), and magnetic resonance angiography (MRA). In addition, some of the participants also had the susceptibility-weighted imaging (SWI). Two neurologists (ZYL and JFQ), who were blinded to the participants' clinical information, measured the CT and MRI parameters simultaneously, and inconsistencies in the data were resolved by discussion. We recorded the lesions located in the basal ganglia: including in the putamen, caudate nucleus and globus pallidus (8); which included hyperdense areas on CT and abnormal signals on each sequence of MRI. Because the basal ganglia are supplied by the middle cerebral artery (MCA), we also recorded the degree of stenosis in bilateral MCA, respectively. We also assessed any pre-existing abnormalities on brain MRI images as follows.

- White matter lesions (WMLs). The severity of WMLs was graded using the four-point scale described by Fazekas et al.
 (17). The WMLs included periventricular hyperintensities (PVHs) and deep white matter hyperintensities (DWMHs), which were separately scored on FLAIR images.
- (2) Global brain atrophy. This was assessed using the ventricular-brain ratio (VBR) (18) on axial TI-weighted images. The width of the bodies of the lateral ventricles were measured half-way between the anterior and posterior limits (a), and the width of the brain was measured at the same level (b). The VBR was then calculated by dividing (a) by (b).
- (3) Medial temporal lobe atrophy (MTLA). MTLA was evaluated using Schelten's scale (19). The investigator judged the severity of MTLA on standard coronal MRI sections using a 0–4 range, with 0 representing no atrophy and 4 representing severe atrophy.
- (4) Middle cerebral artery stenosis (MCA-S). MCA-S was defined as a signal loss of ≥50% and a reduction in the size of the arterial lumen or occlusion in the M1 segment of the MCA, identified using both the targeted maximal intensity projection on MRA and the source images to minimize the overestimation of stenosis that is inherent in the time-of-flight MRA technique (20).
- (5) Enlarged perivascular spaces (EPVSs). According to the Standards for Reporting Vascular Changes on Euroimaging (STRIVE) guidelines, EPVSs are defined as fluid-filled spaces with signal intensities similar to those of cerebrospinal fluid on all of the sequences; that follow the course of penetrating vessels; are linear, round, or ovoid in shape; do not have a hyper-intense rim, to distinguish them from small lacunae; and generally have a diameter <3 mm (21) EPVSs can be detected as punctate or linear hyperintensities on T2-weighted MRI, particularly in the basal

ganglia (BG) and centrum semiovale (CS) (21, 22). EPVSs of small diameter (<3 mm) are often numerous and therefore impractical to count. In the present study, the severities of EPVS formation in the CS (CS-EPVS) and BG (BG-EPVS) were rated according to the number of spaces in the unilateral slice containing the largest number of EPVSs: score 0 = no EPVSs; 1 = 1-10; 2 = 11-20; 3 = 21-40; and $4 \ge 40$ (22).

(6) Silent brain infarcts (SBIs). SBIs were defined as cerebral infarcts that were evident on brain MRI and were not accompanied by overt clinical manifestations, such as rapidly developing clinical symptoms or signs of a focal loss of brain function (23). Most SBI are lacunae, which are visible as focal lesions with approximately the same intensity as cerebrospinal fluid on MRI and have diameters >3mm (24).

Statistical analysis

The continuous variables with normal distributions were present as means and standard deviations, while the variables with skewed distributions were presented as medians and interquartile ranges. And the categorical variables were presented as frequencies and percentages. The normality of variables was tested with a onesample Kolmogorov-Smirnov test. Comparisons of demographic and clinical variables were conducted between the NKHC group and matched group. We set up a logistic regression model step by step to find the putative associated factors of the clinical and imaging variables for NKHC. Firstly, univariate analyses were performed to compare the variables between the two groups to screened out the factors with significant difference, with a value of P <0.05. Secondary, trying to reduce the statistic bias, correlation analyses were conducted to test the collinearity of candidate independent variables. When the correlation coefficient between any of these putative factors was \geq 0.40, then the variable with a lager statistic (with a lower P value) was determine to be included in the next step (25). Thirdly, the logistic regression analyses using a backward stepwise selection strategy were set up to study the putative correlation between these variables and NKHC. The odds ratio (OR) for each independent factor was calculated to compare its strength of the association for NKHC, when all the other factors were held constant. In addition, Spearman correlation analysis was conducted to test the factors that may affecting the resolution time in NKHC group. The significance level was set at 0.05 (two-sided), and statistical analyses were performed using the SPSS 27.0 statistical package (IBM Inc., Armonk, NY, USA).

Results

The characteristics of the participants with NKHC

During the study period, a total of 27 patients (14 female and 13 male) presented with acute or subacute chorea in the setting of

hyperglycemia or diabetes mellitus. However, neuroimaging examination was not available for some patients, which precluded confident diagnosis of NKHC. Ultimately, 20 patients (9 female and 11 male) were included in the analysis, as shown in the flow chart (Figure 1). Supplementary Table 1 compares excluded and included patients, while Table 1 summarizes individual data for each NKHC participant. In the NKHC group, 45% were female, with a mean age of 68.5 \pm 14.9 years. The median blood glucose concentration on admission was 23.1(11.35, 30.58) mmol/L, and the mean HbA1c was 13 \pm 2.82%.

One of the 20 participants with NKHC (No.7) involving their extremities bilaterally showed bilateral hyperdensive signals in their basal ganglia on CT, hyperintensive lesions on T1-weighted MRI, and hypointensive lesions on SWI (Figure 2). Five participants (No. 13, 14, 15, 17 and 18) with unilateral involvement of their extremities showed bilateral hypointensive lesions on SWI.

Comparison of the clinical and imaging variable between the two groups

The results of the univariate analysis are presented in Table 2. Compared to the matched group, participants with NKHC had a higher frequency of irregular usage of glucose-lowering agents or no treatment (75% vs. 46.7%, *P*=0.038), a higher HbA1c level (13 \pm 2.82% vs. 10.57 \pm 2.71%, P<0.001), and worse renal function (55% vs. 20%, *P*=0.005).

The collinearity analysis was conducted for the aforementioned independent variables. The results showed that irregular usage of glucose-lowering agents or no treatment, renal dysfunction, and HbA1c were included in the model. The analysis further revealed that



Selection of patients with NKHC for the present study. MRI, magnetic resonance imaging; CT, computed tomography; NKHC, non-ketotic hyperglycemic chorea. worse renal function (eGFR <60 ml/min/1.73m2) [odds ratio (OR) 7.234, 95% confidence interval (CI) 1.885–27.756, P=0.004] and HbA1c level (OR 1.476, 95% CI 1.144–1.905, P=0.003) were significantly associated with NKHC (R2 = 39.7%) (Supplementary Table 2).

Correlation analysis of resolution time of participants with NKHC

All patients with NKHC received strict glucose control after admission. Seventeen patients of NKHC required additional antiepileptic/anti-psychotic agents. However, no significant correlations were found between the resolution time of chorea symptoms and any other variables, except for the use of additional anti-epileptic/ anti-psychotic agents (r=0.535, P=0.015). The resolution time for participants requiring additional anti-epileptic/anti-psychotic medications was longer than for those who did not require these agents [21(15, 25) vs. 7(6, 10)].

Discussion

To establish a diagnosis of NKHC, a comprehensive differential diagnosis must be conducted, considering various conditions such as vascular diseases, metabolic disorders (including acquired hepatolenticular degeneration and hyperthyroidism), infections (both bacterial and viral encephalitis), immune-mediated diseases, drug side effects (e.g., dopaminergic agents and tardive dyskinesia), carbon monoxide intoxication, and psychogenic chorea (4). Additionally, the presence of abnormalities on MRI/CT in NKHC must be differentiated from physiological and pathological calcification (e.g., Fahr's disease and parathyroid dysfunction), Wilson disease, and carbon monoxide poisoning; such lesions typically manifest as bilateral or symmetrical abnormalities in the basal ganglia, whereas NKHC lesions tend to be unilateral (4). In this study, we carefully reviewed detailed medical records and confirmed the diagnosis of NKHC based on the criteria proposed by Chua et al. (8), after excluding the aforementioned conditions. Our main findings were that elevated HbA1c levels and renal dysfunction (eGFR <60 ml/min/1.73m2) were significantly associated with the development of NKHC.

Previous studies have postulated that a choreiform movement disorder may serve as an early indicator of diabetes (8). This study supports this hypothesis by revealing that a third of the patients with NKHC were diagnosed with diabetes for the first time during the study period. Therefore, patients with hyperglycemia associated with persistent, non-rhythmic, and unilateral or bilateral involuntary movements of their extremities should be suspected of having NKHC. Chorea may affect a wide range of body parts, including a single extremity, the upper and lower extremities unilaterally or bilaterally, the trunk, the neck and head, and also the face. One of the 20 participants with NKHC (No. 7) displayed bilateral involvement of their extremities, which is a relatively rare occurrence according to previous case reports (1, 8). Additionally, in this study, participants more frequently showed left-sided than right-sided lesions (13 cases *vs.* 5 cases, respectively), a rare occurrence.

Case	Age	Sex	DM dura- tion (yr)	BGCA (mmol/L)	HbA _{1c} (%)	Involved site	Hyperdensity on CT	Hyperintensity on T1-MRI	Hypointensity on SWI-MRI	Resolution time (day)	Additional anti-epileptic/ anti-psychotic agents
1	75	F	8	32.8	12.6	face, LUE, LLE	R:PM,CN	R:PM,CN	ND	30	HPD,CZP,TP,AL
2	95	F	DOA	20.3	11.4	face, LUE, LLE, trunk	R:PM,CN,GP	R:PM,CN	ND	9	CZP
3	37	М	10	11.2	7.1	LUE	Negative	R:PM	ND	48	CBZ
4	57	М	DOA	36.6	15.4	LUE	Negative	R:PM	ND	12	CBZ
5	50	М	DOA	10.9	18.3	LUE,LLE	R:PM	R:PM	ND	19	CZP
6	67	F	20	5.9	11.6	LUE,LLE	Negative	R:PM,CN	ND	7	HPD,CZP
7	59	F	10	7.1	16.7	BE	B:PM,CN,GP	B:PM	B:PM,GP	25	HPD,CZP
8	73	М	30	32.6	14.6	LUE,LLE	R:PM,CN	R:PM,CN	ND	15	HPD,RPD
9	87	F	3	18.9	10.4	face, RUE, RLE	L:PM,CN	L:PM,CN	L:PM,CN	17	HPD,CZP
10	56	F	20	29.6	12.9	face, LUE, LLE	Negative	L:PM,CN	ND	20	HPD,CZP
11	54	М	DOA	22	13.3	LUE,LLE	R:PM,CN,GP	R:PM,CN,GP	R:GP	21	HPD,CZP
12	84	М	32	26.9	14.4	RUE,RLE	L:PM,CN,GP	L:PM,CN	L:PM	21	HPD,CZP
13	84	F	10	23.5	13.5	LUE	Negative	R:PM	B:GP	5	None
14	73	М	2	28.3	16.2	face, LUE, trunk	B:PM,CN,GP	B:CN	B:PM,CN,GP	7	None
15	84	F	20	11.8	13.8	LUE,LLE	R:PM	R:PM	B:PM,CN,GP	22	HPD
16	55	F	7	22.7	12.4	face, RUE, RLE	L:PM,CN	L:PM,CN	L:PM	25	HPD,CZP
17	83	М	DOA	26.7	15.7	RUE,RLE	L:PM,CN	L:PM,CN	L:CN,B:PM,GP	14	RPD
18	70	М	5	30.9	11.9	RUE	Negative	L:PM	B:GP	30	CZP
19	74	М	DOA	34.2	11.1	LUE, trunk	Negative	R:PM	ND	13	None
20	52	М	DOA	7.12	7.6	head, neck	Negative	B:CN	Negative	70	CZP

DM, diabetes mellitus; BGCA, blood glucose concentration on admission; DOA, diagnosis of diabetes mellitus on admission; L, left; R, right; B, bilateral; UE, upper extremity; LE, lower extremity; BE, bilateral extremities; PM, putamen; CN, caudate nucleus; GP, globus pallidus; ND, not done; HPD, haloperidol; CZP, clonazepam; CBZ, carbamazepine; AL, alprazolam; TP, tiapride; RPD, risperidone.



FIGURE 2

Brain computed tomography (CT) and magnetic resonance images (MRIs) of participant #7. (A) CT showed bilateral hyperdense lesions in the striatum. (B) T1-weighted MRI showed asymmetrical bilateral hyperintense lesions in the putamen, but no significant changes in the caudate or globus pallidus. (C) Susceptibility-weighted imaging showed bilateral symmetrical hypointense lesions in the putamen and globus pallidus.

We observed an association between renal dysfunction and NKHC. Diabetes mellitus is a leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Previous studies have shown that patients with diabetes and CKD frequently exhibit a choreiform movement disorder, particularly when undergoing dialysis (26-28). The glomerular filtration rate (GFR) is the best overall index of kidney function, estimated to assess the degree of kidney damage and monitor the progression of the disease (29). However, few studies have evaluated the relationship between estimated GFR (eGFR) and NKHC. In the present study, we found that the eGFRs of individuals with NKHC were significantly lower than those without NKHC. An eGFR <60 ml/min/1.73m² is low, indicating impaired renal excretion (29). The resulting accumulation of toxic metabolites, such as urea, guanidines, and various amino acids, in the brain can lead to neuronal dysfunction through various mechanisms, including a neurotransmitter imbalance, an impairment in ATPase pump activity, calcium overload, and changes in plasma osmotic pressure (30-32). The renal impairment and subsequent decrease of eGFR in patients with NKHC may be caused by factors beyond diabetes alone, such as age, drug toxicity, and hypertension. As a cross-sectional study, it is not appropriate to establish a causal relationship between NKHC and renal dysfunction. However, no significant difference in demographic characteristics or comorbidity was found between individuals with NKHC and those without in our study. We believe that an eGFR <60 ml/min/1.73m² may suggest metabolic disorders in the body that could accelerate the onset of NKHC. The specific pathogenesis of renal dysfunction in patients with NKHC requires further investigation, involving measures such as urinary albumin concentration, renal imaging, and renal biopsy.

The correlation between blood glucose level and the incidence of NKHC remains unconfirmed. The blood glucose concentration on admission (BGCA) of individuals with NKHC exhibited substantial variation, spanning a range from 5.9 mmol/L to 36.6 mmol/L. This variance may be attributed to the patients' admission status, which could be influenced by factors such as food intake and the utilization of glucose-lowering agents. To minimize the impact of these potential

confounding factors on the study findings, we employed a control group with BGCAs matched to those of the NKHC group.

The HbA1c values of individuals with NKHC (mean \pm SD, 13 \pm 2.82%) were significantly higher than those of the matched control group, with a previous systematic review and meta-analysis of 176 patients with diabetic striatopathy yielding a similar median HbA1c (13.1%) (8). A high HbA1c indicates elevated blood glucose concentrations over the preceding 2-3 months (33), suggesting that patients with poorly controlled diabetes during this period are more prone to developing NKHC. Previous studies have shown that the anaerobic pathway is used to provide energy for the basal ganglia during hyperglycemia (34), but this pathway is inefficient, especially in individuals with non-ketotic hyperglycemia rather than ketotic hyperglycemia. Therefore, basal ganglia dysfunction due to energy deficiency may be responsible for the development of chorea. This finding could potentially serve as a significant pointer towards a deeper comprehension of the intricate mechanisms behind NKHC.

In the present study, we observed that individuals with NKHC exhibited a higher frequency of basal ganglia lesions that appeared as hyperdensive lesions on CT (60%), hyperintensive lesions on T1weighted MRI (100%), and hypointensive lesions on SWI (90.0%, n=11) (Table 1). While the precise etiology underlying these imaging characteristics remains elusive, pathological anatomy and MRI studies have suggested that these distinct signals may be attributed to reactive astrocytosis in the basal ganglia (7, 11, 35, 36). The hyperintensive signal on T1-weighted MRI could be attributed to the impact of oxidative stress on the hydration of cytoplasmic proteins in the swollen gamistocytes that characterize long-standing hyperglycemia. Furthermore, these astrocytes also express metallothionein, containing zinc, which is thought to be the cause of the hypointense signal on SWI (37). In our study, there were 11 participants with NKHC underwent SWI-MRI in the present study. Of these, four patients presented with unilateral chorea of the extremities, but had bilateral hypointensities in the basal ganglia on SWI. However, they did not have corresponding

TABLE 2 Comparison of the clinical characteristics and brain imaging variable between the NKHC group and matched group.

	NKCH N=20	Matched N=60	$t/\chi^2/z$ -value	P-value
Clinical variables				
Age, years*	68.45 ± 15.3	68.18 ± 14.9	0.069	0.945
Sex, Female ^{\dagger}	9(45%)	27(45%)	0	1
Prior Stroke ^{\dagger}	7(35%)	9(15%)	3.75	0.102
Hypertension [†]	12(60%)	37(61.7%)	0.018	1
Dyslipidemia [†]	4(20%)	25(41.7%)	3.047	0.109
Coronary Artery Disease [†]	1(5%)	3(5%)	0	1
Duration of DM, years [‡]	6(0, 17.5)	7(2, 12.5)	-0.430	0.667
Irregular usage of glucose-lowering agents †	15(75%)	28(46.7%)	4.844	0.038
No SMBG^{\dagger}	18(90%)	44(73.3%)	2.389	0.214
BGCA, mmol/L [‡]	23.1(11.35, 30.58)	23.05(11.5, 29.9)	-0.056	0.956
HbA _{1c} , %*	13 ± 2.82	10.57 ± 2.71	3.504	<0.001
eGFR<60ml/min/1.73m ^{2‡}	11(55%)	12 (20%)	8.97	0.005
ALT, U/L [‡]	18.3 (12.3, 32.4)	18.6 (12.4, 30.4)	-0.072	0.942
TC, mmol/L*	4.78 ± 0.9	5.36 ± 1.49	-1.642	0.105
Imaging variables				
MCA-S [†]	8 (40%)	21 (35%)	0.162	0.790
DWMH [‡]	1 (0, 2)	1 (1, 2)	-0.323	0.746
PVH [‡]	1 (1, 2)	1 (1, 2)	-0.736	0.461
MTLA [‡]	2 (1, 2.75)	2 (1, 2.75)	-1.002	0.316
VBR*	0.21 ± 0.032	0.21 ± 0.045	0.501	0.618
EPVS (BG) [‡]	1(1, 2)	1(1, 2)	-1.089	0.276
EPVS (CS) [‡]	1(0, 1)	1(0.25, 2)	-1.675	0.094
SBIs [‡]	0(0, 2)	0.5(0, 2)	-0.574	0.566

*Mean (SD), t-test; [†] n (%), Fisher's exact test; [‡] Median (interquartile range), Mann–Whitney U test; SMBG, self-monitoring of blood glucose; BGCA, blood glucose concentration on admission; eGFR, Estimated Glomerular Filtration Rate; ALT, serum alanine aminotransferase activity; TCH, serum total cholesterol concentration; Hyper-CT, hyperdense lesions on computed tomography; Hyper-TIWI, hyperintense lesions on the T1 sequence; Hypo-SWI, hypointense lesions on the SWI sequence; MCA-S, middle cerebral artery stenosis; DWMH, deep white matter hyperintensities; PVH, periventricular hyperintensities; MTLA, medial temporal lobe atrophy; VBR, ventricle/brain ratio; EPVS (BG), enlarged perivascular spaces in the basal ganglia; EPVS (CS), enlarged perivascular spaces in the centrum semiovale; SBIs, silent brain infarcts; NKCH, non-ketotic hyperglycemic chorea. The bold: with a P value < 0.05.

hyperintensive bilateral lesions of their basal ganglia on T1weighted MRI, and only one of them had corresponding hyperdensive lesions on CT. It is noteworthy that these four participants were relatively old (84, 73, 84, and 83 years), and therefore these symmetrical signals (bilateral hypointensities in the basal ganglia on SWI-MRI) may represent age associated mineralization. Indeed, abnormal asymmetric lesions in the basal ganglia are responsible for NKHC (13). This study emphasizes the need for a multimodal MRI approach to assess NKHC.

In particular, we further investigated other MRI features of NKHC in patients. The middle cerebral artery supplies the basal ganglia, and there was no significant difference in the prevalence of middle cerebral artery stenosis between the participants with and without NKHC. The cells located in the periventricular region, deep white matter, and basal ganglia are particularly sensitive to ischemia (38). However, no severe PVHs or DWMHs were identified in the participants with NKHC. A previous study showed that hypoperfusion induced by hyperglycemia has a substantial effect on the transport of oxygen and nutrients, which results in cerebral degeneration and atrophy (39). However, the atrophy of the brains (indicated by both MTLA and VBR) of participants with NKHC did not differ from those without in the present study. The Rotterdam Scan Study (40) and a previous systematic review (41) suggested that there are close associations between epidemiological predictors of SBIs and diabetes mellitus. However, despite NKHC being a diabetes mellitus-related syndrome, the SBIs of the participants with NKHC were no worse than those of the non-NKHC group. This study adds to our understanding of the MRI features of NKHC, but further research is needed to fully understand its etiology and pathogenesis.

Our study found that resolution time of participants with additional anti-epileptic/anti-psychotic agents was longer than those without. The prognosis of chorea associated with nonketotic hyperglycemia has been reported as good generally. Chorea can be rapidly controlled by normalization of glycemia (42, 43). Resolution of the lesions seen in imaging studies was found to be slower than the clinical course (44). Previous study demonstrated abnormal imaging located on basal ganglia can persist for several months to years despite correction of hyperglycemia (1). Our study found that most patients with NKHC require additional anti-epileptic/anti-psychotic agents beside strict glucose control, which might be contributed to the prominently longer resolution time.

The present study's strengths lie in its analytical approach, which, to the best of our knowledge, is the first of its kind for NKHC. Previous studies available to us were predominantly case reports and descriptive in nature. Additionally, we compared patients with NKHC with a matched control group and evaluated the correlation between NKHC and a comprehensive list of MRI variables (WMLs, VBR, MTLA, MCA-S, EPVS, and SBIs). However, this study also had some limitations. Firstly, the sample size was relatively small. Secondly, due to the retrospective nature of the study, we were unable to follow up with patients and assess whether neuroimaging abnormalities returned to normal following correction of hyperglycemia. Finally, despite our attempts to obtain imaging data prior to hospitalization or during follow up visits, it was often challenging to achieve this goal in a retrospective case-control study. A further prospective study dedicated to NKHC would help address these limitations.

Conclusion

We discovered a significant independent association between patients with NKHC and higher HbA1c levels as well as renal dysfunction. These findings may contribute to the body of knowledge surrounding NKHC in the literature and offer a valuable clue for future investigations into its underlying mechanisms.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Ethics Committee of the Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants' legal guardians/next of kin because the retrospective design of the study and the minimal risk associated for the participants.

Author contributions

Z-YL: Data curation, Formal analysis, Project administration, Writing – review & editing. Z-HL: Data curation, Formal analysis, Writing – review & editing. J-FQ: Conceptualization, Data curation, Formal analysis, Writing – original draft. Y-KC: Conceptualization, Supervision, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Dongguan Science and Technology of Social Development Program (20211800905182) and Guangdong Basic and Applied Basic Research Foundation (2020B1515120055).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fendo.2023.1323942/ full#supplementary-material

References

1. Oh SH, Lee KY, Im JH, Lee MS. Chorea associated with non-ketotic hyperglycemia and hyperintensity basal ganglia lesion on T1-weighted brain MRI study: a meta-analysis of 53 cases including four present cases. *J Neurol Sci* (2002) 200 (1-2):57–62. doi: 10.1016/s0022-510x(02)00133-8

2. Bedwell SF. Some observations on hemiballismus. *Neurology* (1960) 10:619–22. doi: 10.1212/WNL.10.6.619

3. Yahikozawa H, Hanyu N, Yamamoto K, Hashimoto T, Shimozono K, Nakagawa S, et al. Hemiballism with striatal hyperintensity on T1-weighted MRI in diabetic patients: a unique syndrome. *J Neurol Sci* (1994) 124(2):208–14. doi: 10.1016/0022-510x(94)90328-x

4. Dong M, JY E, Zhang L, Teng W, Tian L. Non-ketotic hyperglycemia choreaballismus and intracerebral hemorrhage: A case report and literature review. *Front Neurosci* (2021) 15:690761. doi: 10.3389/fnins.2021.690761

5. Cosentino C, Torres L, Nuñez Y, Suarez R, Velez M, Flores M. Hemichorea/ hemiballism associated with hyperglycemia: report of 20 cases. *Tremor Other Hyperkinet Mov (N Y).* (2016) 6:402. doi: 10.7916/D8DN454P

6. Ondo WG. Hyperglycemic nonketotic states and other metabolic imbalances. Handb Clin Neurol (2011) 100:287-91. doi: 10.1016/B978-0-444-52014-2.00021-5

7. Abe Y, Yamamoto T, Soeda T, Kumagai T, Tanno Y, Kubo J, et al. Diabetic striatal disease: clinical presentation, neuroimaging, and pathology. *Intern Med* (2009) 48 (13):1135–41. doi: 10.2169/internalmedicine.48.1996

8. Chua CB, Sun CK, Hsu CW, Tai YC, Liang CY, Tsai IT. "Diabetic striatopathy": clinical presentations, controversy, pathogenesis, treatments, and outcomes. *Sci Rep* (2020) 10(1):1594. doi: 10.1038/s41598-020-58555-w

9. Lee BC, Hwang SH, Chang GY. Hemiballismus-hemichorea in older diabetic women: a clinical syndrome with MRI correlation. *Neurology* (1999) 52(3):646-8. doi: 10.1212/wnl.52.3.646

10. Shan DE, Ho DM, Chang C, Pan HC, Teng MM. Hemichorea-hemiballism: an explanation for MR signal changes. *AJNR Am J Neuroradiol* (1998) 19(5):863–70.

11. Ohara S, Nakagawa S, Tabata K, Hashimoto T. Hemiballism with hyperglycemia and striatal T1-MRI hyperintensity: an autopsy report. *Mov Disord* (2001) 16(3):521–5. doi: 10.1002/mds.1110

12. Fujioka M, Taoka T, Matsuo Y, Hiramatsu KI, Sakaki T. Novel brain ischemic change on MRI. Delayed ischemic hyperintensity on T1-weighted images and selective neuronal death in the caudoputamen of rats after brief focal ischemia. *Stroke* (1999) 30 (5):1043–6. doi: 10.1161/01.str.30.5.1043

13. Cherian A, Thomas B, Baheti NN, Chemmanam T, Kesavadas C. Concepts and controversies in nonketotic hyperglycemia-induced hemichorea: further evidence from susceptibility-weighted MR imaging. *J Magn Reson Imaging* (2009) 29(3):699–703. doi: 10.1002/jmri.21672

14. Herath HMMTB, Pahalagamage SP, Senanayake S. Case report of hyperglycemic nonketotic chorea with rapid radiological resolution. *BMC Med Imaging* (2017) 17 (1):54. doi: 10.1186/s12880-017-0228-2

15. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabetes Med* (1998) 15(7):539–53. doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med* (2009) 150(9):604–12. doi: 10.7326/0003-4819-150-9-200905050-00006

17. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. *Neurology* (1993) 43(9):1683–9. doi: 10.1212/wnl.43.9.1683

18. Victoroff J, Mack WJ, Grafton ST, Schreiber SS, Chui HC. A method to improve interrater reliability of visual inspection of brain MRI scans in dementia. *Neurology* (1994) 44(12):2267–76. doi: 10.1212/wnl.44.12.2267

19. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. *J Neurol Neurosurg Psychiatry* (1992) 55(10):967–72. doi: 10.1136/jnnp.55.10.967

20. Fu JH, Chen YK, Chen XY, Mok V, Wong KS. Coexisting small vessel disease predicts poor long-term outcome in stroke patients with intracranial large artery atherosclerosis. *Cerebrovasc Dis* (2010) 30(5):433–9. doi: 10.1159/000319574

21. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* (2013) 12(8):822–38. doi: 10.1016/S1474-4422(13)70124-8

22. Potter GM, Chappell FM, Morris Z, Wardlaw JM. Cerebral perivascular spaces visible on magnetic resonance imaging: development of a qualitative rating scale and its observer reliability. *Cerebrovasc Dis* (2015) 39(3-4):224–31. doi: 10.1159/000375153

23. Song J, Kim OJ, Kim HS, Bae SJ, Hong SP, Oh D, et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of silent brain infarction. *Int J Mol Med* (2010) 25(5):819–23. doi: 10.3892/ijmm_00000410

24. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. *Lancet Neurol* (2007) 6(7):611–9. doi: 10.1016/S1474-4422(07)70170-9

25. Qu JF, Chen YK, Luo GP, Zhao JH, Zhong HH, Yin HP. Severe lesions involving cortical cholinergic pathways predict poorer functional outcome in acute ischemic stroke. *Stroke* (2018) 49(12):2983–9. doi: 10.1161/STROKEAHA.118.023196

26. Kiryluk K, Khan F, Valeri A. Acute chorea and bilateral basal ganglia lesions in a hemodialysis patient. *Kidney Int* (2008) 73(9):1087–91. doi: 10.1038/sj.ki.5002768

27. Lin JJ. Generalized chorea in the syndrome of acute bilateral basal ganglia lesions in patients with diabetic uremia. *J Clin Neurosci* (2011) 18(9):1266–8. doi: 10.1016/j.jocn.2011.01.021

28. Dicuonzo F, Di Fede R, Salvati A, Palma M, de Mari M, Baldassarre GD, et al. Acute extrapyramidal disorder with bilateral reversible basal ganglia lesions in a diabetic uremic patient: diffusion-weighted imaging and spectroscopy findings. *J Neurol Sci* (2010) 293(1-2):119–21. doi: 10.1016/j.jns.2010.03.001

29. Levey AS, Coresh J. Chronic kidney disease. Lancet (2012) 379(9811):165-80. doi: 10.1016/S0140-6736(11)60178-5

30. Hamed SA. Neurologic conditions and disorders of uremic syndrome of chronic kidney disease: presentations, causes, and treatment strategies. *Expert Rev Clin Pharmacol* (2019) 12(1):61–90. doi: 10.1080/17512433.2019.1555468

31. Safarpour Y, Vaziri ND, Jabbari B. Movement disorders in chronic kidney disease - A descriptive review. *J Stroke Cerebrovasc Dis* (2021) 30(9):105408. doi: 10.1016/j.jstrokecerebrovasdis.2020.105408

32. Baumgaertel MW, Kraemer M, Berlit P. Neurologic complications of acute and chronic renal disease. *Handb Clin Neurol* (2014) 119:383–93. doi: 10.1016/B978-0-7020-4086-3.00024-2

33. Nathan DM, Balkau B, Bonora E, Borch-Johnsen K, Buse JB, Colagiuri S, et al. International Expert Committee International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. *Diabetes Care* (2009) 32(7):1327–34. doi: 10.2337/dc09-9033

34. Guisado R, Arieff AI. Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain. *Metabolism* (1975) 24(5):665-79. doi: 10.1016/0026-0495(75)90146-8

35. Nath J, Jambhekar K, Rao C, Armitano E. Radiological and pathological changes in hemiballism-hemichorea with striatal hyperintensity. *J Magn Reson Imaging* (2006) 23(4):564–8. doi: 10.1002/jmri.20548

36. Matsuda M, Hashimoto T, Shimizu Y, Watabe O, Hattori T, Tabata KI, et al. Coexistence of hemidystonia and hemiballism in a diabetic patient with striatal hyperintensity on T1-weighted MRI. *J Neurol* (2001) 248(12):1096–8. doi: 10.1007/pl00007829

37. Shimada A, Uemura T, Yamamura Y, Kojima S, Morita T, Umemura T. Localization of metallothionein-I and -II in hypertrophic astrocytes in brain lesions of dogs. J Vet Med Sci (1998) 60(3):351–8. doi: 10.1292/jvms.60.351

38. Brown WR, Moody DM, Challa VR, Thore CR, Anstrom JA. Venous collagenosis and arteriolar tortuosity in leukoaraiosis. *J Neurol Sci* (2002) 203-204:159-63. doi: 10.1016/s0022-510x(02)00283-6

39. Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. *J Neurosci Res* (2017) 95(4):943–72. doi: 10.1002/jnr.23777

40. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. *Stroke* (2003) 34(2):392–6. doi: 10.1161/01.str.0000052631.98405.15

41. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. *BMC Med* (2014) 12:119. doi: 10.1186/s12916-014-0119-0

42. Higa M, Kaneko Y, Inokuchi T. Two cases of hyperglycemic chorea in diabetic patients. *Diabetes Med* (2004) 21(2):196-8. doi: 10.1111/j.1464-5491.2004.01096.x

43. Branca D, Gervasio O, Le Piane E, Russo C, Aguglia U. Chorea induced by nonketotic hyperglycaemia: a case report. *Neurol Sci* (2005) 26(4):275–7. doi: 10.1007/ s10072-005-0471-0

44. Lai PH, Tien RD, Chang MH, Teng MM, Yang CF, Pan HB, et al. Choreaballismus with nonketotic hyperglycemia in primary diabetes mellitus. *AJNR Am J Neuroradiol* (1996) 17(6):1057-64.

Glossary

	I		
NKHC	Non-ketotic hyperglycemic chorea		
DM	Diabetes mellitus		
BGCA	Blood glucose concentration on admission		
HbA _{1c}	Glycosylated hemoglobin		
eGFRs	Estimated glomerular filtration rates		
ALT	Serum alanine aminotransferase activity		
ТСН	serum total cholesterol concentration		
CT	Computed tomography		
MRI	Magnetic resonance imaging		
SMBG	Self-monitoring of blood glucose		
T1WI	T1-weighted imaging		
T2WI	T2-weighted imaging		
MRA	Magnetic resonance angiography		
SWI	Susceptibility-weighted imaging		
Hyper-CT	hyperdense lesions on computed tomography		
Hyper-TIWI	hyperintense lesions on the T1 sequence		
Hypo-SWI	hypointense lesions on the SWI		
MCA	Middle cerebral artery		
WMLs	White matter lesions		
PVHs	Periventricular hyperintensities		
DWMHs	Deep white matter hyperintensities		
VBR	Ventricular-brain ratio		
MTLA	Medial temporal lobe atrophy		
MCA-S	Middle cerebral artery stenosis		
EPVSs	Enlarged perivascular spaces		
BG	Basal ganglia		
CS	Centrum semiovale		
SBIs	Silent brain infarcts		
OR	odds ratio		
ROC	Receiver operating characteristic		
AUCs	Areas under the ROC curve		
IQR	Interquartile range		
SD	Standard deviation		
CI	Confidence interval		
CKD	Chronic kidney disease		
ESKD	End-stage kidney disease.		